Lancet Lond Engl 397:17361748
In phase 3 adult clinical trials, most notably the SURMOUNT-1 study, tirzepatide produced significant and sustained reductions in body weight and metabolic parameters
This combination of effects results in eating fewer calories, maintaining stable blood sugar, and feeling fuller for much longer
That said, the effect size of this circadian alignment is likely small compared to the overall impact of the drug itself
Sudo M, Li Y, Hiro T, Takayama T, Mitsumata M, Shiomi M, Sugitani M, Matsumoto T, Hao H, Hirayama A
That can unlock some similar features